Influence of different dose α-lipoic acid on blood glucose and C-reaction protein in type 2 diabetic patients with macroangiopathy

Abstract

Objective To discuss the influence of different dose α-lipoic acid on blood glucose and C-reaction protein(CRP) in type 2 diabetic patients with macroangiopathy. Methods Seventy-two cases type 2 diabetic patients with macroangiopathy were divided randomly and voluntarily into the conventional dose group(n=36) and high dose group(n=36). The patients of conventional dose group were given conventional dose α-lipoic acid(300 mg/d) based on glucose treatment while high dose group were given high dose α-lipoic acid(600 mg/d) based on glucose treatment, the courses were all 15 d. The fasting blood glucose(FBG), 2 h postprandial blood glucose(2 hBG), serum CRP of before and after treatment of between the two groups and safety during the treatment were compared. Results The FBG, 2 hBG and CRP of before and after treatment were respcetively (9.24±2.18) mmol/L and (8.18±1.38) mmol/L, (13.26±3.17) mmol/L and (11.26±1.63) mmol/L, (21.52±4.17) mg/L and (14.72±3.73) mg/L; (9.26±2.04) mmol/L and (5.82±1.27) mmol/L, (13.52±2.45) mmol/L and (8.92±1.04) mmol/L, (22.65±4.67) mg/L and (8.61±1.52) mg/L, all groups decreased obviously, the differences were statistically significant compared to that of before treatment(t=4.265, 4.654, 4.956 and 5.562, 6.254, 7.654, P<0.05), and the high dose group showed more lower(t=5.353, 5.783, 6.257, P<0.05). After treatment, ALT((37.26±9.64) U/L), AST((38.22±7.04) U/L), BUN((7.25±1.52) mmol/L) and Scr((55.25±11.25) mmol/L) of all groups increased obviously than pre-treatment((33.53±6.37) U/L, (33.15±7.16) U/L, (5.43±4.67) mmol/L, (53.15±13.65) mmol/L), but the differences were no statistically significant compared to that of before treatment(t=-2.061, -2.165, -1.455, -0.689, P<0.05), and there were also no statistical significance between the two groups(t=2.125, 3.026, 1.235, 1.035, P<0.05). Conclusion α-lipoic acid can obviously decrease the blood glucose and CRP in type 2 diabetic patients with macroangiopathy, which has a significant dose effect relationship, and is safe and worthy of clinical application. Key words: Type 2 diabetes; Macroangiopathy; α-lipoic acid; Blood glucose; C-reaction protein